NCT01840683已完成不适用
An Open-label, Single Center Study to Evaluate the Efficacy and Safety of Heparin-induced Extracorporeal Lipoprotein Precipitation (H.E.L.P.) Therapy as a Treatment for Non-exudative (Dry) Age-related Macular Degeneration (AMD)
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 22
- 试验地点
- 2
- 主要终点
- To evaluate the effects of H.E.L.P. therapy on the best corrected visual acuity (BCVA) in patients with non-exudative (dry) AMD.
研究概览
简要总结
This is an open-label, single center clinical investigation to evaluate the efficacy and safety of Heparin-induced Extracorporeal Lipoprotein Precipitation (H.E.L.P.) Therapy as a treatment for non-exudative (dry) Age-related Macular Degeneration (AMD). A total of 14 clinic visits are scheduled, one baseline visit, 8 visits for H.E.L.P. therapy treatments (to be performed over a period of 12 weeks for each patient) and 5 follow-up visits to be performed one week following the 4th H.E.L.P. therapy session and 12 weeks, 24 weeks, 36 weeks and 52 weeks after the final H.E.L.P. therapy session.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 50 Years 至 90 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diagnosis of non-exudative (dry) AMD
- •Male or female, between 50 and 90 years
- •Presence of soft, confluent drusen in study eye
- •At least one large (>125 μm) drusen
- •Visual acuity (VA) between 20/32 and 20/100 Early treatment Diabetic Retinopathy Study (ETDRS) vision
- •Fibrinogen level >100mg/dL
- •Willing to continue lipid-lowering medication throughout the treatment phase if such medication was taken already before the study
- •Willing to continue regular supplemental intake of Age related Eye Disease Study (AREDS) vitamins or comparable supplements throughout the study course
- •Written informed consent
- •Exclusion Criteria (related to the underlying disease):
- •Any evidence of wet AMD in either eye
- •History of treatment for wet AMD in either eye
- •Geographic atrophy involving fovea in study eye
- •Fellow eye <20/400 VA
- •Presence of cataract requiring treatment during study
- •Presence of glaucoma requiring new treatment during study
- •Presence of diabetic or other vascular retinopathy
- •Previous retinal laser or surgical therapy
- •Epiretinal membrane in study eye
- •Any other ocular condition requiring therapy during the study
- •Exclusion Criteria (General):
- •Participation in another clinical trial within 30 days
- •Concurrent participation in another clinical trial
- •Pregnancy or lactation
- •Inability to give or understand informed consent
- •Inability to maintain treatment and follow-up schedule
- •Hypersensitivity to fluorescein
- •Test positive for infectious status from HIV-, HBV- and HCV- infection
- •Exclusion Criteria (H.E.L.P. Apheresis):
- •Heparin intolerance
- •Heparin induced thrombocytopenia (HIT) II
- •Hemorrhagic diathesis
- •Ulcers in the gastrointestinal area
- •Hemorrhage
- •Coagulation disorder and neoplasm
- •Liver diseases
- •Severe heart failure and valvular defect
- •Condition following apoplexia
- •During pregnancy and lactation
- •C1 esterase inhibitor deficiency or hereditary complement component 3 (C3) deficiency
排除标准
- 未提供
结局指标
主要结局
To evaluate the effects of H.E.L.P. therapy on the best corrected visual acuity (BCVA) in patients with non-exudative (dry) AMD.
时间窗: Change from Baseline in the best corrected visual acuity (BCVA) at Week 24 after completion of H.E.L.P. therapy
次要结局
- To evaluate the effects of H.E.L.P. therapy on the change in drusen area as assessed by colour photography.(Change from Baseline to Weeks 24 and 52 after completion of H.E.L.P. therapy)
- To evaluate the effects of H.E.L.P. therapy in area of abnormal autofluorescence as assessed by Fundus Autofluorescence (FAF).(Change from Baseline to Weeks 24 and 52 after completion of H.E.L.P. therapy)
- To evaluate the effects of H.E.L.P. therapy on overall visual functioning as assessed by the Visual Functioning Questionnaire (VFQ)-25 test.(Change from Baselineto Weeks 24 and 52 after completion of H.E.L.P. therapy)
- To evaluate the safety of H.E.L.P. therapy by assessing laboratory tests and vital signs.(Baseline and at all HELP therapy sessions being conducted after Baseline within 12 weeks.)
- To evaluate the effects of H.E.L.P. on the integrity of the outer retinal bands as assessed by Optical Coherence Tomography (OCT)(Change from Baseline in integrity of the outer retinal bands at Weeks 24 and 52 after completion of H.E.L.P. therapy)
- To evaluate the effects of H.E.L.P. therapy on the best corrected visual acuity (BCVA).(Change from Baseline to Week 52 after completion of H.E.L.P. therapy)
- To evaluate the effects of H.E.L.P. therapy on the AREDS severity scale as assessed by colour photography.(Change from Baseline to Weeks 24 and 52 after completion of H.E.L.P. therapy)
- To evaluate the effects of H.E.L.P. therapy on the incidence and change in area of geographic hypo autofluorescence as assessed by fundus autofluorescence images.(Change from Baseline to Weeks 24 and 52 after completion of H.E.L.P. therapy)
- To evaluate the effects of H.E.L.P. on the drusen volume as assessed by Optical Coherence Tomography (OCT)(Change from Baseline to Weeks 24 and 52 after completion of H.E.L.P. therapy)
- To evaluate the safety of H.E.L.P. therapy by assessing adverse events (AEs).(At all H.E.L.P. therapy sessions and follow-up visits being conducted after Baseline within 12 weeks and 12, 24, 36 and 52 weeks after completion of the H.E.L.P. therapy.)
- To evaluate the safety of H.E.L.P. therapy by physical examination.(At all H.E.L.P. therapy sessions being conducted after Baseline within 12 weeks and 52 weeks after completion of the H.E.L.P. therapy.)
研究者
研究点 (2)
Loading locations...
相似试验
进行中（未招募）
2 期
Fruquintinib Combined With Tislelizumab and HAIC in Patients With Advanced Colorectal Liver Metastases Cancer Who Failed Standard TherapyColorectal CancerNCT05435313Fudan University39
招募中
1 期
U87 CAR-T in Patients With Advanced Head and Neck TumorsNasopharynx CancerHead and Neck CancerNCT06614686Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd20
招募中
2 期
Adjuvant Adebrelimab Plus Apatinib for Participants With HCC at High-risk of Recurrence After Curative ResectionCarcinoma, HepatocellularNCT06454578Qilu Hospital of Shandong University30
尚未招募
不适用
Surufatinib Combined With Toripalimab and HAIC in the Treatment of Inoperable or Metastatic Intrahepatic CholangiocarcinomaIntrahepatic CholangiocarcinomaNCT06313554Fudan University63
招募中
1 期
A Single-arm, Open-label Clinical Study to Evaluate the Efficacy and Safety of VRT106 in Combination With Chemotherapy for Resectable Pancreatic CancerPancreatic CancerNCT06758544Guangdong Provincial People's Hospital18